MedTrace Logo

Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis

NCT01939093 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-09-11

No results posted yet for this study

Summary

The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.

Conditions

  • Methamphetamine-induced Psychosis

Interventions

DRUG

Diazepam

If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.

DIETARY_SUPPLEMENT

Vitamin B1-6-12

All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.

DRUG

Stugeron

All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.

Sponsors & Collaborators

  • Thanyarak Institute

    collaborator UNKNOWN

  • National Research Council of Thailand

    collaborator OTHER_GOV

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Viroj Verachai, M.D. · Thanyarak Institute on Drug Abuse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939093 on ClinicalTrials.gov